Navigation Links
Hebrew University research holds promise for development of new osteoporosis drug
Date:10/4/2010

Jerusalem, October 4, 2010 Researchers at the Hebrew University of Jerusalem have discovered a group of substances in the body that play a key role in controlling bone density, and on this basis they have begun development of a drug for prevention and treatment of osteoporosis and other bone disorders.

The findings of the Hebrew University researchers have just been published in the American journal PNAS (Proceedings of the National Academy of Sciences).

The research group working on the project is headed by Prof. Itai Bab of the Bone Laboratory and Prof. Raphael Mechoulam of the Institute of Drug Research at the Hebrew University, and includes post-doctoral fellow Reem Smoum and doctoral students Gary Millman, Orr Ofek, Alon Bajayo, Joseph Tam, Vardit Kram and associates from the United States.

Osteoporosis is the most widespread degenerative disease in the Western world and is expressed in the loss of bone mass and the weakening of bone structure, contributing to frequent bone fractures, disability and even death. The loss of bone mass in osteoporosis is caused by internal destruction of the bone tissue. With age, the quantity of bone tissue that is lost is greater than that which is created, which leads to the decrease in bone density.

In their current research, the researchers found that the bone cells produce a series of substances composed of fatty acids and amino acids called "acyl amides." They then analyzed their precise chemical composition, created synthetic versions of them, and examined their effect on bone cell cultures.

In experiments on mice, they discovered that one of the compounds in the group of synthetic materials, oleoyl serine, increased bone density in both healthy and osteoporotic mice. They also found that the osteoporotic mice were actually missing the oleoyl serine in their bones. These findings, say the researchers, can serve as the basis for new drugs that can both prevent bone lo
'/>"/>

Contact: Jerry Barach
jerryb@savion.huji.ac.il
972-258-82904
The Hebrew University of Jerusalem
Source:Eurekalert  

Page: 1 2

Related biology news :

1. Scent on demand: Hebrew University scientists enhance the scent of flowers
2. Hebrew University scientists reveal mechanism that triggers differentiation of embryo cells
3. Hebrew University professors work leads to FDA approval for product
4. Hebrew University researchers neutralize tumor growth in embryonic stem cell therapy
5. Promising new treatment for Alzheimers suggested based on Hebrew University research
6. Hebrew U. researchers shed light on the brain mechanism responsible for processing of speech
7. Ben-Gurion U. developing new computer techniques to analyze historic Hebrew and Arabic documents
8. Alert status area in brain discoved by Hebrew University scientists
9. Regulatory role of key molecule discovered at Hebrew U.
10. Hebrew University, American researchers show trigger to stem cell differentiation
11. JDRF, Pfizer, Hadassah Medical and the Hebrew University announce collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Hebrew University research holds promise for development of new osteoporosis drug
(Date:8/26/2015)... 2015 The report "Multi-Factor Authentication (MFA) ... Application (Travel & Immigration, Government, Banking, Defense, Commercial Security, ... 2020", published by MarketsandMarkets, Multi-Factor Authentication Market is expected ... a CAGR of 17.7% between 2015 and 2020. ... igures spread through 169 P ages ...
(Date:8/20/2015)... , Aug. 20, 2015 The wearable ... that are active and healthy. However, wearable technology ... hospital environment to help improve diagnostic capabilities and ... from the Wearable Technologies Conference 2015 , ... applications for wearables in healthcare.    ...
(Date:8/18/2015)... Aug. 18, 2015  Navitas today announced ... to the Submission Content Management webinar scheduled ... non-profit forum. Dedicated to the Implementation of Regulatory ... platform for industry, vendors, health authorities, consultants ... work towards a standard method of implementing ...
Breaking Biology News(10 mins):Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3
... A new study published this week in the journal ... mixing of cold, deep waters from below can change sea ... occurs in a huge region of the ocean that takes ... climate patterns, particularly global warming. Using a new measurement ...
... cell found in the trillions in our brain have made ... injury and disease such as stroke. A University of Bristol ... how astrocyte cells respond to neurological trauma. The star-shaped ... glial cell that comprise one of two main categories of ...
... research team from the School of Basic Medical ... Radix Achyranthis Bidentatae can inhibit advanced glycation end ... cortex, and improve learning and memory capabilities in ... on advanced glycation end product accumulation is associated ...
Cached Biology News:Study explains Pacific equatorial cold water region 2Study explains Pacific equatorial cold water region 3Key target responsible for triggering detrimental effects in brain trauma identified 2
(Date:9/2/2015)... Mich. and LIBERTYVILLE, Ill. (PRWEB) , ... ... ... NSF International, a leading provider of regulatory compliance, quality systems, analytical testing, ... LLC, a consulting firm with expertise in medical device products/processes development, design ...
(Date:9/2/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/cqsxmg/gene_therapy ... report "Gene Therapy - Technologies, Markets and Companies" ... gene therapy are difficult to estimate as there is ... marketed in China since 2004. ... The estimates are based on epidemiology of diseases to ...
(Date:9/2/2015)... Australian prostate cancer technology company Minomic International Ltd has ... science that uses its patented antibody. The ... cancer diagnostic test known as MiCheck® next year, was ... peer-reviewed Australian Museum Eureka Science Prize for Excellence ... is awarded for ground breaking research that has only ...
(Date:9/2/2015)... Biovista Inc. freut sich, ... 2015 bekanntgeben zu können. Hierbei handelt es sich ... Biovista unterstützt mit seiner Möglichkeit der Analyse ... Krankheiten als denen, für die ein Medikament ursprünglich ... Team bei der Wylder Nation Foundation bei der ...
Breaking Biology Technology:NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 2NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 3NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 4NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 5NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 6NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 7Global Gene Therapy Market Study 2015-2024 - Technologies, Markets and Companies Analysis 2Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 2Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 3Biovista sponsert die Forschung von Wylder Nation Foundation zum Thema Mangel an saurer Sphingomyelinase 2
... Testing Market, FULLERTON, Calif., March 6 ... announced today that it has launched the ... integrated work cell which,consolidates chemistry and immunoassay ... to the company,s work cell family,combines Beckman ...
... Earlier Stage ... Chronic Kidney Disease Patients, CAMBRIDGE, Mass., March 6 ... launch of the phosphate binder,Renvela(R) (sevelamer carbonate) for dialysis patients, ... additional,approvals for the product., Genzyme has submitted a marketing ...
... SOUTH EASTON, Mass., March 6 Pressure,BioSciences, Inc. (Nasdaq: ... host,a teleconference to discuss its 2007 financial results and ... the teleconference either,by telephone or through a live web-cast. ... Wednesday March 12, 2008, Time: 4:30 p.m. Eastern ...
Cached Biology Technology:Beckman Coulter Releases the High-Volume UniCel(R) DxC 880i Integrated Work Cell 2Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients 2Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients 3Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients 4Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients 5Pressure BioSciences, Inc. to Discuss 2007 Financial Results and Provide Business Update 2
... was developed using a protein engineering approach that ... pocket of wild-type DNase I. These changes markedly ... The result is a versatile enzyme that has ... ability to maintain at least 50% of peak ...
... iTaq DNA polymerase is ... suitable for both conventional and ... is supplied at a concentration ... and includes 250 units polymerase, ...
hnRNP U (H-94)...
... is causing shortages in your laboratory or fellow ... unwanted distractions, problems and delays. • ... and endeavour! Bring us your idea and let ... We work under ISO 9001 quality assurance in ...
Biology Products: